Bayer confirms 2025 targets after solid start to the year
EBITDA before special items decreases to €4.08 billion (7.4%)
EBITDA before special items decreases to €4.08 billion (7.4%)
These observations are procedural in nature and none of them are related to data integrity
The inspection concluded with 6 observations and none of them were related to Data Integrity
This approval authorizes the company to export Ibuprofen to the Chinese markets
Durable pain relief from a single MM-II injection and its cartilage-protective effects in OA modelsfeatured in two peer-reviewed articles
Access to NIPT, TB and Rare Disease diagnostics to benefit thousands of patients nationwide
Genomics is transforming the future of modern medicine and treatment modalities across specialties
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
Padmanabhan brings over two decades of extensive experience in FMCG sector
Subscribe To Our Newsletter & Stay Updated